For research use only ยท Not for human or animal consumption
// Growth Hormone & Endocrine

Tesamorelin Research Guide

A synthetic analogue of growth hormone-releasing hormone, approved as Egrifta for one HIV-related indication. Covers the published randomized trials.

4Sources
3FAQs
4Min read
For research use only. Not for human consumption.
01

What is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor. As a GHRH analogue, it stimulates the synthesis and release of the body’s own growth hormone (Dhillon, 2011).

That puts it in a different class from ghrelin receptor agonists such as ipamorelin: GHRH analogues act through the pituitary GHRH receptor, while ghrelin receptor agonists act through a separate receptor.

02

Research areas studied

The findings below come from cell, animal and published clinical research. They describe what studies have examined and reported, not effects of any research material.

Why most of the research is clinical

Tesamorelin was developed as a medicine, so most of its published research consists of randomized trials of the approved pharmaceutical product in people with HIV, rather than cell or animal studies.

The phase 3 trials

A randomized trial of 412 patients with HIV and abdominal fat accumulation compared tesamorelin with placebo over 26 weeks, with change in visceral adipose tissue measured by CT as the primary endpoint. It reported a decrease in visceral adipose tissue and an increase in IGF-I compared with placebo, and more withdrawals because of adverse events in the tesamorelin group (Falutz et al., 2007). A 2011 review of the two 26-week phase 3 trials reported that the visceral fat change was maintained to week 52 with continued use and reversed after discontinuation, and that subcutaneous fat did not change to a clinically significant extent. Reported adverse events included injection-site reactions and events associated with growth hormone, such as arthralgia, headache and peripheral edema (Dhillon, 2011).

Liver fat studies

A 6-month randomized trial in 50 people with HIV examined visceral fat and liver fat; fasting glucose rose in the tesamorelin group at 2 weeks but was not significantly different at 6 months (Stanley et al., 2014). A 12-month multicentre trial in 61 people with HIV and non-alcoholic fatty liver disease measured hepatic fat fraction, and reported more localized injection-site complaints with tesamorelin than with placebo (Stanley et al., 2019).

Regulatory status and limits of the evidence

Tesamorelin is approved as Egrifta, the first product indicated for reducing excess abdominal fat in patients with HIV-associated lipodystrophy (Dhillon, 2011). The clinical evidence applies to that population and to the approved product. The review authors noted that longer-term clinical experience is still needed, and research material is not an approved medicine.

03

Storage and handling

Like most research peptides, Tesamorelin is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.

When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.

04

Quality and COA

Every Zero Zero Collection product page has a View COA link. Certificates of analysis come from independent third-party testing by Freedom Diagnostics and are posted on our Quality page where available. A COA reports what the testing lab measured for one specific batch, so match the lot number on your vial to the certificate. Our FAQ explains how to read a COA.

05

Tesamorelin FAQ

What class of compound is tesamorelin?

It is a synthetic analogue of growth hormone-releasing hormone (GHRH), which stimulates the release of the body's own growth hormone.

Is tesamorelin approved by the FDA?

The pharmaceutical product Egrifta is approved for one indication: reducing excess abdominal fat in patients with HIV-associated lipodystrophy. Research material is not an approved medicine.

How is tesamorelin different from ipamorelin?

Tesamorelin is a GHRH analogue. Ipamorelin is a pentapeptide that acts at the ghrelin receptor. They act through different receptors.

07

References

  1. Dhillon S (2011). Drugs. PubMed 21668043
  2. Falutz J, Allas S, Blot K, et al. (2007). N Engl J Med. PubMed 18057338
  3. Stanley TL, Feldpausch MN, Oh J, et al. (2014). JAMA. PubMed 25038357
  4. Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Lancet HIV. PubMed 31611038

For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.

Get 15% Off Your First Order

Join the Zero Zero Collection list for restock alerts, new COAs and member pricing. Research use only.